MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-cell Lymphoma

Trial Profile

MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2020.
    • 09 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 08 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top